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AUromodulin Storage Diseases: Clinical Aspects and Mechanisms
Francesco Scolari, MD, Gianluca Caridi, PhD, Luca Rampoldi, PhD, Regina Tardanico, MD,
Claudia Izzi, MD, Doroti Pirulli, PhD, Antonio Amoroso, MD, Giorgio Casari, PhD, and
Gian Marco Ghiggeri, MD
The recent discovery of mutations in the uromodulin gene (UMOD) in patients with medullary cystic kidney
isease type 2 (MCKD2), familial juvenile hyperuricemic nephropathy (FJHN), and glomerulocystic kidney disease
GCKD) provides the opportunity for a revision of pathogenic aspects and puts forth the basis for a renewed
lassification. This review focuses on clinical, pathological, and cell biology advances in UMOD-related pathologi-
al states, including a review of the associated clinical conditions described to date in the literature. Overall, 31
MOD mutations associated with MCKD2 and FJHN (205 patients) and 1 mutation associated with GCKD (3
atients) have been described, with a cluster at exons 4 and 5. Most are missense mutations causing a cysteine
hange in uromodulin sequence. No differences in clinical symptoms between carriers of cysteine versus polar
esidue changes have been observed; clinical phenotypes invariably are linked to classic MCKD2/FJHN. A common
otif among all reports is that many overlapping symptoms between MCKD2 and FJHN are present, and a
eparation between these 2 entities seems unwarranted or redundant. Cell experiments with mutant variants
ndicated a delay in intracellular maturation and export dynamics, with consequent uromodulin storage within the
ndoplasmic reticulum (ER). Patchy uromodulin deposits in tubule cells were found by means of immunohistochem-
stry, and electron microscopy showed dense fibrillar material in the ER. Mass spectrometry showed only
nmodified uromodulin in urine of patients with UMOD mutations. Lack of uromodulin function(s) is associated with
mpairments in tubular function, particularly the urine-concentrating process, determining water depletion and
yperuricemia. Intracellular uromodulin trapping within the ER probably has a major role in determining tubulointer-
titial fibrosis and renal failure. We propose the definition of uromodulin storage diseases for conditions with
roven UMOD mutations. Am J Kidney Dis 44:987-999.
2004 by the National Kidney Foundation, Inc.
NDEX WORDS: Uromodulin; Tamm-Horsfall protein; medullary cystic kidney disease (MCKD); familial juvenile
yperuricemic nephropathy (FJHN); glomerulocystic kidney disease (GCKD).
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GENAL CYSTIC DISEASES are the major
group of inherited renal conditions in hu-
ans, representing a leading cause of end-stage
enal disease in the world. Polycystic kidney
isease (PKD), in both the dominant and reces-
ive variants, accounts for most of the relevant
linical conditions. However, nephronophthisis
NPH), medullary cystic kidney disease (MCKD),
nd dominant glomerulocystic kidney disease
GCKD) together still cause a relevant clinical
mpact, mostly in children.1
Recent advances in the field of molecular
enetics provide the opportunity for revision of
he pathogenic aspects of renal cystic diseases
nd put forth the basis for a renewed classifica-
ion. Starting from 1997, causative mutations in
genes for NPH (NPHP1, NPHP2, NPHP3, and
PHP4) have been identified,2-5 and based on
unctional genomics, some links between the
PH family and PKD genes were described.
In parallel to these developments, seminal
ork by Hart et al6 led to the discovery of
utations in UMOD, the gene encoding uro-
odulin, in large pedigrees with MCKD type 2
MCKD2; Mendelian Inheritance in Man 603860)
nd familial juvenile hyperuricemic nephropathy
merican Journal of Kidney Diseases, Vol 44, No 6 (December), 2FJHN; Mendelian Inheritance in Man 162000).
his finding later was confirmed by other
roups7-14 and recently was extended to autoso-
al dominant GCKD.10 Uromodulin (also known
s Tamm-Horsfall protein) was found to be accu-
ulating in patch aggregates in all these condi-
ions, suggesting a common pathogenesis.9,10
hus, once again, on the basis of the molecular
nd functional similarities, the mentioned condi-
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SCOLARI ET AL988ions were tentatively grouped under the defini-
ion of UMOD-related diseases.
Therefore, 2 separate lines of evidence sup-
ort the concept that the NPH and MCKD,
lthough previously considered the recessive and
ominant counterparts of the same disease com-
lex, should be differentiated clearly and classi-
ed more simply according to the molecular
dvances deriving from functional genomics.
This review focuses on the clinical, pathologi-
al, molecular, and cell biology advances in
MOD-related pathological states, including a
etailed review of clinical conditions in which
MOD mutations have been reported. Data for
n animal model with UMOD genetic ablation
lso are discussed. Together, these findings sup-
ort the need for separation of diseases related to
MOD mutations from other cystic kidney dis-
ases, and we propose, on the basis of pathologi-
al and experimental results, the definition of
romodulin storage renal diseases.
HISTORICAL BACKGROUND ON UROMODULIN
STRUCTURE AND FUNCTIONS
Uromodulin is a specific kidney protein pro-
uced in the thick ascending limb (TAL) of the
oop of Henle.15,16 In its mature form, it is
ainly an extracellular protein anchored by gly-
osyl phosphatidylinositol functional group at
he luminal face of tubular epithelia. Uromodulin
s excreted, representing the most abundant pro-
ein in urine of healthy individuals. Based on the
ypical gelling properties and localization at the
AL, where permeability to water typically is
ow, it was historically hypothesized that uro-
odulin’s major function is to maintain water
mpermeability at this site.17 Successive studies
nvestigated many other putative functions of the
rotein that was later considered a primary de-
ense against bacteria (discussed next). The struc-
ural features of uromodulin have been reviewed
xtensively by Serafini-Cessi et al18 in a recent
ssue of this journal. However, a few structural
utlines could make understanding easier of fine
echanisms involved in pathogenesis of UMOD-
elated diseases. Uromodulin is a very highly
onserved protein with a high degree of se-
uence similarity (77% to 83% identities) with
at, mouse, dog, and cow homologues.19-25 The
rotein includes a high content of cysteine resi-
ues (48 of 640 amino acids; 7.5%), suggesting a eomplex conformational architecture. Uromodulin
as an N-terminal 24–amino acid signal peptide
absent in the mature protein),19 4 calcium-binding
pidermal growth factor (cbEGF)-like domains, a
ona pellucida–like domain from amino acid 336
o 585, and a glycosyl phosphatidylinositol anchor
ttachment site at position 614.
Despite significant speculation, the function of
romodulin remains unclear. Extensive research
n uromodulin function supports the notion that
he protein acts as a protective agent against
acteria in the urinary tract, competitively inhib-
ting adhesion of the type 1-fimbriated Esche-
ichia coli to the urothelial surface.26-31 Uro-
odulin also has been considered the culprit of
idney pathological states that lead to the intralu-
inal formation of casts and/or stones, owing to
ts tendency to form a gel or aggregates.32-38
More recently, the clinical relevance of uro-
odulin has been emphasized by evidence that
CKD2 and FJHN arise from mutations of the
MOD gene.6
UROMODULIN AND MEDULLARY CYSTIC
KIDNEY DISEASE TYPE 2: THE
UNEXPECTED LINK
Traditionally, MCKD belongs to a heteroge-
eous group of inherited cystic tubulointerstitial
ephritis, named NPH-MCKD complex.1 The 2
iseases share clinical features (polyuria, polydip-
ia, and anemia), macroscopic pathological char-
cteristics (cysts primarily located at the cortico-
edullary border), and renal histological
haracteristics (tubular atrophy, interstitial fibro-
is, and cell infiltration). NPH and MCKD also
re characterized by 3 distinguishing features;
ode of inheritance (recessive in NPH and domi-
ant in MCKD), age of onset for end-stage renal
isease (developing in childhood or adolescence
n patients with NPH and adulthood in patients
ith MCKD), and extrarenal organ involvement
tapetoretinal degeneration and liver fibrosis in
atients with NPH, gout and/or hyperuricemia in
atients with MCKD).39 The term NPH-MCKD
omplex has been proposed as a compromise
ppellation because of the inability to show a
lear clinical and pathological distinction be-
ween them.36
Molecular genetics has definitely contributed
o differentiate between NPH and MCKD. In the
arly 1990s, the first gene locus for NPH to
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UROMODULIN STORAGE DISEASES 989uman chromosome 2q12-q13 was mapped, and
ecently, 3 new genes were discovered.2-5 Inter-
stingly, NPH genes colocalize with PKD genes
o the primary cilium.4,5,40-44 Previously thought
o be vestigial cellular organelles, primary cilia
unction as flow-sensitive mechanosensors.44 All
roducts of mutated genes in NPH, ie, nephrocys-
in 1, inversin, nephrocystin 3, and nephroreti-
in, and the main proteins involved in autosomal
ominant PKD, ie, polycystin-1 and polycys-
in-2, are cilia proteins. These data collectively
uggest an unexpected link between the molecu-
ar mechanisms of pathogenesis in these cystic
iseases. Conversely, 2 loci for dominant MCKD,
CKD1 and MCKD2, have been localized to
hromosome 1q21 and 16p12, respectively.45,46
CKD1 was mapped in a few kindreds from
yprus that were characterized by diffuse renal
ysts, hyperuricemia, and chronic renal failure.
robably, MCKD1 and MCKD2 cannot be readily
ifferentiated on clinical grounds, and additional
escriptions of families with MCKD1 are needed
o show the clinical boundaries between the 2
enetic entities. The gene for FJHN, a phenotype
hyperuricemia, gout, progressive renal failure at
n early age, and dominant inheritance) very
imilar to MCKD2, later was mapped to 16p12,
n a region overlapping with the MCKD2 lo-
us.47-49 Genetic heterogeneity of FJHN was
hown in some families, resulting to be unlinked
o the 16p12 locus.9,47,50 That MCKD2 and FJHN
oci mapped to the same critical region raised the
uestion of whether MCKD2 and FJHN were
llelic variants of the same disease entity.49 In
002, Hart et al6 identified 4 novel UMOD gene
utations segregating with the disease pheno-
ype in 3 families with FJHN and 1 family with
CKD2, providing evidence that MCKD2 and
JHN arise from mutation of the UMOD gene
nd are allelic disorders.
Furthermore, the existence of a yet to be
dentified third locus has been shown in a few
eports of MCKD/FJHN families unlinked to
oth MCKD1 and MCKD2 loci.51,52
HETEROGENEITY OF CLINICAL CONDITIONS
ASSOCIATED WITH UROMODULIN
GENE MUTATIONS
After the seminal observation by Hart et al,6 a
ew confirmatory reports have been published.7-14
MOD mutations also were reported in a family pith autosomal dominant GCKD.10 The pres-
nce of a genetic defect in UMOD in MCKD2,
JHN, and GCKD (discussed next) showed that
hese 3 conditions are allelic. Overall, 8 families
ith MCKD2 and 24 families with FJHN have
een described.6-13 A common motif to all re-
orts is that so many overlapping symptoms
etween MCKD2 and FJHN are present that
eparation between these 2 entities seems artful
nd probably clinically useless. For this reason,
n the following sections devoted to the clinical
escription of UMOD-related diseases and geno-
ype-phenotype correlations, MCKD2 and FJHN
re discussed together.
edullary Cystic Kidney Disease 2 and
amilial Juvenile Hyperuricemic Nephropathy
The main clinicopathologic features, includ-
ng the incidence of renal failure, hyperuricemia/
rimary gout, and renal cysts, reported to date in
atients carrying UMOD mutations are listed in
able 1. In Table 1, which lists the original
lassification, the order of presentation of the
ffected family members follows the position of
he nucleotide/amino acid change starting from
he N-terminus. Overall, 33 families with 31
ifferent UMOD mutations, including 205 af-
ected members, have been described. Fourteen
utations affect the cbEGF-like domains, with
lusters in the 2 highly conserved exons 4 and 5;
7 additional mutations localize to a highly con-
erved protein region (residues 149 to 280) that
as no sequence similarity to any reported do-
ain. In the first case, ie, mutations in the cbEGF-
ike domains, most changes affect cysteine resi-
ues and are predicted to prevent a disulfide
ond formation and therefore perturb the protein
onformation. An additional mutation involves
sparagine residue 128 at a predicted Ca bind-
ng site, possibly loosing the calcium co-coordi-
ating segment predicted to stabilize the tertiary
tructure.18 Eight amino acid changes mapping
ithin the conserved region between residue 149
nd 280 involve cysteine residues that probably
ontribute to protein folding, whereas 9 involve
olar amino acid residues. Clinical features of
he potentially different cohorts were similar: of
3 patients with mutations in 1 of the 4 predicted
bEGF domains, 41 patients (77%) had chronic
enal failure and 43 patients (81%) also had
rimary hyperuricemia with gout, whereas only
Table 1. Families With MCKD/FJHN and 32 Different UMOD Mutations Reported in the Literature to Date
Family
No. Origin
No. of
Affected
Individuals
Chronic
Renal
Failure Gout Cysts
Renal Histological
Characteristics Classification
Nucleotide
Change Protein Change
UMOD
Domain Reference
1 Japan 2 2 2 NA NA FJHN 156 T3G C52W EGF II 11
2 Belgium 1 1 — 1 NA FJHN 176A3C D59A EGF II 9
3 Austria 8 6 8 3 NA FJHN 230G3A C77Y EGF II 8
4 NA 6 6 — 3 3/TIN MCKD2 278del12/ins9 V93_G97delinsAASC EGF II 7
5 Not reported 3 3 2 1 * MCKD2 307G3T G103C EGF II 6
6 Belgium 1 1 1 1 NA FJHN 334T3C C112R EGF III 9
7 Italy 2 2 2 NA NA FJHN 376T3C C126R EGF III 9
Austria 2 NA 2 NA NA FJHN 376T3C C126R EGF III 8
8 Spain NA NA NA NA NA FJHN 383A3G N128S EGF III 8
9 Japan 7 6 7 NA NA FJHN 403T3A C135S EGF III 11
10 Not reported 9 9 9 NA 1/TIN FJHN 443G3A C148Y EGF III 6
11 Italy 3 3 3 — NA MCKD2 444T3C C148W EGF III 10
12 Italy 17 11 11 4 1/TIN MCKD2 449G3A C150S — 10
13 France 3 2 0 1 NA FJHN 509G3A C170Y — 9
14 Not reported 38 28 34 NA 3/TIN FJHN 529_555del H177_R185del — 6, 13
15 Belgium 11 5 6 3 3/TIN FJHN 553C3A R185S — 9
16 France 3 3 1 NA NA FJHN 563_661del AA188-221del — 9
17 Japan 3 3 2 NA NA FJHN 584G3T C195F — 11
18 Japan 4 4 4 NA NA FJHN 605G3C W202S — 11
19 Morocco 1 1 1 — NA FJHN 610C3G R204G — 9
20 Belgium 1 1 1 — NA FJHN 649T3G C217G — 9
21 Not reported NA NA NA NA NA FJHN 649T3C C217R — 6
22 France 7 7 4 2 2/TIN FJHN 665G3C R222P — 9
23 Not reported 2 1 2 1 1/TIN FJHN/MCKD2 665G3A C223Y — 12
24 France 8 7 1 1 1/TIN FJHN 674C3T T225M — 9
25 NA 3 3 3 3 3/TIN MCKD2 674C3A T225L — 7
26 Japan 20 17 15 NA NA FJHN 707C3T P236L — 11
27 NA 3 3 3 1 1/TIN MCKD2 744C3G C248W — 7
28 Spain 5 5 3 NA 3/TIN FJHN 784G3A C255Y — 8
Spain 23 10 9 3 3/TIN FJHN/MCKD2 784G3 A C225Y(het/hom) — 14
29 France 1 1 1 NA NA FJHN 844T3C C282R EGF IV 9
30 Spain FJHN 898T3G C300G EGF IV 8
31 Italy 3 3 3 3 3/TIN glomerular
cysts
GCKD 943T3C C315R EGF IV 10
32 Italy 8 1 6 1 3/TIN MCKD2 950G3A C317Y EGF IV 10
Abbreviations: NA, not available; TIN, tubulointerstitial nephritis; het, heterozygous state; hom, homozygous state.
*Renal histological characteristic reported for 3 other members of the family at necroscopy showing hyalin deposit in tubular cell and cyst dilatation in 1 individual.
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UROMODULIN STORAGE DISEASES 9910 patients had renal cysts. However, in numer-
us cases, the presence of renal cysts had not
een evaluated. By comparison, chronic renal
ailure was found in 111 of 152 patients (73%)
ith mutation involving the 149 to 280 region,
00 patients (66%) had hyperuricemia/gout, and
8 patients (12%) had renal cysts. Therefore,
ost patients with UMOD mutations have a
ombination of chronic renal failure and gout
rrespective of type and site of mutation. Person-
lized data on specific clinical symptoms, such
s urine osmolality and uric acid levels, are
canty and are reviewed in the sections on related
echanisms.
The clinical issue about the artful differentia-
ion of MCKD2 and FJHN on the basis of
edullary cysts in families classified as MCKD2
nd hyperuricemia in FJHN warrants a com-
ent. Overall, the diagnosis in families with
utations in the cbEGF domains was MCKD2 in
cases and FJHN in 11 cases, whereas 3 and 13
amilies with mutations in the 149 to 280 region
ere identified as MCKD2 and FJHN, respec-
ively.6-13 Moreover, we described a family com-
osed of 17 affected individuals carrying the
utation C150S, in which half the patients pre-
ented a pure FJHN phenotype, characterized by
solated hyperuricemia and/or gout, and the re-
aining half had renal cysts at the corticomedul-
ary junction.6 In other words, differentiation of
CKD2 and FJHN apparently is not supported
y a different phenotype and appears conceptu-
lly artful. For this reason, other investiga-
ors12,49,53 have proposed the term MCKD2/
JHN complex as an alternative, and we are fully
n agreement with this point of view.
lomerulocystic Kidney Disease
GCKD is a rare disorder characterized by
iffuse glomerular cysts caused by dilatation of
owman’s space.54 Tubular cysts in the renal
ortex and medulla may coexist, but they are
ncommon. GCKD may occur as a sporadic
isorder in association with other renal diseases,
uch as glomerulonephritis,55 systemic lupus er-
thematosus,56 and hemolytic uremic syn-
rome.57 Alternatively, GCKD is inherited as
art of a wide spectrum of malformations, as in
ral-facial-digital syndrome,58 or associated with
aturity-onset diabetes (MODY5). In the latterase, mutations of the hepatocyte nuclear fac- cor-1 gene (HNF-1) have been reported.59
nterestingly, a mutation in HNF-1 recently
lso was found in 1 family with atypical FJHN
ssociated with renal cysts, urogenital malforma-
ions, and diabetes.60 Unfortunately, the pres-
nce of cysts affecting glomeruli was not ex-
luded in all patients in this kindred because
lomerular cysts cannot be differentiated readily
rom those localized in tubuli by means of ultra-
onography; a renal biopsy is required for a
ifferential diagnosis. Finally, another family with
utosomal dominant GCKD has been described.54
A missense mutation (C315R) in the UMOD
ene recently was reported in a family segregat-
ng autosomal dominant GCKD.10,61 The cys-
eine to arginine change maps to cbEGF domain
V,10 where other UMOD mutations have been
ound in patients with MCKD2/FJHN. It seems
orth reporting here that all members of the
nique family with GCKD and UMOD muta-
ions showed severe impairment of urine-concen-
ration capability and hyperuricemia and
robably differ from those carrying MODY5-
ssociated HNF-1mutations. The phenotype of
he index family we described10 directly shares
ome features with MCKD2 and FJHN, and it is
ifficult to establish how unique these features
re among GCKD families. Data for urine-
oncentration capability in the previously de-
cribed pedigrees with dominant GCKD are
canty. In the only family for which a detailed
nalysis of urinary parameters is available,62
rine concentration after overnight water depriva-
ion was altered, and few patients had hyperurice-
ia. Moreover, coexistence of glomerular and
edullary cysts has been described in different
eports,63,64 and additional studies addressing
his clinical issue in families with dominant
CKD are warranted.
A few pathogenic aspects relative to GCKD in
xperimental models and humans reinforce the
riginal finding of a role of uromodulin in GCKD.
ne point is that glomerular cysts may be gener-
ted experimentally by ureteric obstruction in
etal sheep,65 therefore suggesting that early me-
hanical forces may inhibit full development of
he glomerular tuft. Conversely, dense aggre-
ates of uromodulin in tubular cells protruding in
he lumen have been described in patients with
CKD, mimicking, in some way, an obstructiveondition. Moreover, histochemical studies
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SCOLARI ET AL992howed an abnormal presence of uromodulin
ithin glomerular cysts.66,67 Therefore, these
ata suggest that a possible mechanism for glo-
erular cysts could be partial tubular obstruction
nd consequent reflux of urine (and uromodulin)
n Bowman’s space.
In conclusion, HNF-1 and UMOD appear to
e the relevant genes in GCKD. This finding
ay underscore a casual relationship between
he 2, but a pathogenic link cannot be ruled out.
ecent molecular studies indicate that a specific
NF-1 element is present in cis in the UMOD
romoter and that uromodulin (together with
enes involved in murine polycystic kidneys) is
ownregulated in mice lacking HNF-1/ for
argeted engineering.68
THE LESSON FROM MICE WITH GENETIC
ABLATION OF Umod
Results of targeted genetic ablation of Umod
n mice recently were published independently
y 2 different groups.30,31 As expected, Umod
eficiency predisposed mice to bladder coloniza-
ion by type-1 fimbrated E coli. This is the first
emonstration of a role of the protein in innate
rinary defense in vivo. Unfortunately, data for
rine-concentrating capability and other bio-
hemical parameters, such as acid uric levels in
nockout mice, have not been reported, prevent-
ng a comparison with patients with MCKD2/
JHN/GCKD. Surprisingly, results from renal
istological examination, obtained at 2 to 3
onths of age, do not show the typical fea-
ures of tubulointerstitial fibrosis and cysts. In
greement with this finding, Bates et al31 re-
orted that no cysts or fibrosis were present in
heir mice with Umod ablation, even after 24
onths. Together, data on Umod/mice conclu-
ively document the absence of any morpho-
ogical defects observed in humans with
MOD mutations. Therefore, it seems reason-
ble to hypothesize that renal histological changes
bserved in humans are more directly the result
f an alteration in uromodulin processing and
torage within tubule cells than the consequence
f the protein absence. Data for delayed cell
aturation of mutated uromodulin,10 discussed
n the following section, reinforce this hypoth-
sis. sFINE MECHANISMS RELATED TO DELAYED
CELL MATURATION AND STORAGE
Immunohistological analysis of the kidney in
atients with UMOD mutations turned out to be
rucial to outline basic features of uromodulin
enal expression in these patients, stimulating
dditional in vitro experiments in renal cells.
ooking at both MCKD2 and GCKD renal bi-
psy specimens, uromodulin was found in patchy
eposits in the cytoplasm along the TAL of
enle. This pattern of uromodulin deposition,
hown in Fig 1, was described first by Rampoldi
t al10 and Dahan et al.9 These deposits probably
oincide with the fibrillar material in the endo-
lasmic reticulum (ER) shown by electron mi-
roscopy. However, the immunogold assay was
ot available; hence, there is no conclusive evi-
ence that the fibrillar material is uromodulin.
Because mutations affecting disulfide bonds,
s well as those reducing calcium-binding affin-
ty, most likely cause misfolding of the global
rotein structure, it was hypothesized that these
hanges could lead to delayed maturation and
ence intracellular accumulation in tubular cells
f patients carrying UMOD mutations. Experi-
ents with renal cells in vitro support this possi-
ility.10 The effect of 4 different UMOD mis-
ense mutations identified in patients with
CKD2/FJHN and GCKD and affecting cys-
eine residues 148, 150, 315, and 317 was ana-
yzed by means of transient transfection of wild-
ype and mutant constructs in the cell lines
EK293 and HeLa, which do not normally ex-
ress uromodulin. The amount of protein ex-
osed on the plasma membrane was dramatically
educed in mutant-transfected cells. Colocaliza-
ion experiments showed that delay of mutant
xport to the plasma membrane was determined
y longer retention in the ER. At short times after
ransfection, most wild-type uromodulin local-
zed to the Golgi apparatus, whereas mutant
soforms mainly localized in the ER, with little,
f any, signal in the Golgi. Wild-type uromodulin
ehaves in denaturing conditions like mutated
soforms, confirming the central role of proper
rotein folding in uromodulin maturation steps.
ccumulation of mutant uromodulin in the ER is
f particular interest because this is the site for
onformation stabilization of any protein by di-
ulfide isomerases that should be hampered in
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UROMODULIN STORAGE DISEASES 993he case of uromodulin-mutated isoforms. The
R has a resident machinery based on chaperons
hat assists protein folding and ensures that only
roperly folded proteins move along the secre-
ory pathway.69 Accordingly, unfolded proteins
re bound to chaperons, retained in the ER,70 and
ltimately degraded in the cytosol. The mecha-
ism of degradation appears to be complex and
nvolves ubiquitin, ER-ubiquitin–conjugating en-
ymes, and the proteosome complex.71,72
Failure of correct folding and sorting triggers
Fig 1. Immunohistochemical examination with an-
iuromodulin antibodies of kidney samples from pa-
ients with MCKD2. (A) Kidney sections 0.3-m thick
ere incubated first with monoclonal antiuromodulin
ntibodies (1032A clone; Cedarlane, Hornby, Ontario,
anada), followed by incubation with goat antimouse
mmunoglobulin G linked to biotin. Staining was with
eveloped streptavidin peroxidase and diaminobenzi-
in. Intracellular aggregates of mutant uromodulin are
vident in both cases. (Original magnification 100.)
B) Transmission electron microscopic examination of
he same patient as A shows accumulating dense
aterial, mostly in the ER. (Original magnification
5,700.)he so-called ER stress response, which involves sdifferent pathways known as unfolded protein
esponse and ER overload response, the latter
nvolving nuclear factor-B induction as media-
or of an inflammatory response. Further investi-
ation will be needed to assess whether cell
tress by ER accumulation of unfolded mutant
romodulin may trigger the unfolded protein
esponse and ER overload response and, eventu-
lly, programmed cell death.73 Analysis of uri-
ary uromodulin content is in full agreement
ith the idea of accumulation of unfolded uro-
odulin in tubular cells. In the report by
ampoldi et al,10 a marked decrease in urinary
romodulin levels consistent with the immunohis-
ochemistry observation of uromodulin patch de-
osits in tubular cells was shown in 1 MCKD2
amily. Urinary uromodulin content in patients
ith FJHN was investigated thoroughly by Da-
an et al,9 who showed a consistent decrease in
atients with UMOD mutations compared with
ealthy subjects and patients with chronic renal
ailure from other causes. Chemical and mass
pectrometry analysis showed the presence of
nly wild-type uromodulin in urine from patients
ith FJHN.9 Together, these observations sug-
est that mutated uromodulin accumulates in
ubular cells owing to misfolding, whereas the
ild-type protein is processed normally and ex-
reted in urine. Nevertheless, because reduced
rinary excretion of uromodulin has been re-
orted in several nephropathies, it is not clear
hether the reduction observed in patients with
CKD2/FJHN may be secondary to distal tu-
ule damage.74,75
PATHOLOGICAL EXAMINATION AND
MECHANISMS OF GROSS SYMPTOMS
Diffuse tubulointerstitial fibrosis is a constant
athological finding in all patients with MCKD2/
JHN undergoing renal biopsy.9,10 A concomi-
ant feature is the presence of tubule dilatations,
eaching, in some cases, the dignity of tubular
ysts. Tubule basement membrane appears dupli-
ated in some segments; however, this feature
lso is present in other nephropathies with an
dvanced stage of renal involvement.1 As dis-
ussed previously, severe impairment of urinary-
oncentrating capability is a major and almost
onstant clinical symptom in all patients with
CKD/FJHN, whereas hyperuricemia is not con-tant and often is associated with renal cysts.6-13
I
c
f
p
a
t
D
l
s
p
t
w
c
f
p
a
p
v
t
(
a
m
r
t
r
i
t
o
t
d
s
w
t
c
c
o
d
s
2
t
o
m
T
b
g
c
r
s
c
m
M
i
p he follo
0
SCOLARI ET AL994t is of note that some pathological and biochemi-
al features, such as tubulointerstitial fibrosis,
ormation of medullary and cortical cysts (in
atients with MCKD2 and GCKD, respectively),
nd hyperuricemia remain difficult to explain on
he basis of the protein putative function(s).
efect in the Urine-Concentrating Process
Uromodulin expression is exclusive of epithe-
ial cells of the TAL,15,16 which are nephron
egments characterized by high electrolyte/water
ermeability.18 For this reason, it was proposed
hat uromodulin has a role in salt transport and
ater impermeability at this level, a process
rucial for urine concentration. Personalized data
or morning urine osmolality are available for 32
atients, 7 patients described by Bleyer et al13
nd 25 patients from our cohort (G.M. Ghiggeri,
ersonal observation). All except 2 patients had
alues less than 800 mOsm/L, and values lower
han 600 mOsm/L were present in 26 patients
Fig 2). Therefore, low urine osmolality is an
lmost constant finding in patients with UMOD
utations. Water reabsorption by the tubule is
egulated by a complex transmembrane system
hat includes aquaporin and ion channels (for
Fig 2. Correlation between serum uric acid level a
utations of UMOD.10 For this correlation, only affe
orning urine osmolality values were plotted against s
n urine-concentrating capability and serum uric acid
atients with hyperuricemia. The best fit was given by t
.74275 (P< 0.001).eview, see Agre and Kozona76), and it currently ms unknown how uromodulin could interact with
hem. Experimental data support the hypothesis
f involvement of uromodulin in salt uptake in
he TAL because studies of rats fed different
ietary salt loads showed that uromodulin mes-
enger RNA and protein levels were increased
ith a high-salt diet. The failure of uromodulin
o properly form the water barrier in the TAL
ould explain the marked defect in the urine-
oncentrating process that determines low urine
smolality in patients affected by these disor-
ers.77,78 Water income in the TAL would reduce
odium chloride reabsorption by the TAL Na-K-
Cl cotransporter, responsible for 25% of the
otal sodium renal uptake. This would affect not
nly urine-concentrating capability, but also
aintenance of the countercurrent gradient.
ubulointerstitial Fibrosis
Tubulointerstitial fibrosis is constituted mainly
y deposition of type I and III interstitial colla-
ens. Interstitial collagen deposition represents a
ommon mechanism acting in many, if not all,
enal diseases evolving to chronic renal failure. It
hould arise from a complex series of events
ulminating in renal infiltration by nonresident
e osmolality in 26 patients with MCKD2 and proven
atients from 3 families with MCKD2 were enrolled.
uric levels. The strong correlation between the defect
uggests a mechanism linked with fluid deprivation in
wing curve: Yab * log(x)⁄X^2c * exp(x) with R2nd urin
cted p
erum
level sacrophages, cytokine production, and stimula-
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UROMODULIN STORAGE DISEASES 995ion of collagen synthesis by tubular epithelial
ells and fibroblasts. Although uromodulin may
e implicated in several steps of the fibrotic
ascade, any conclusion on the mechanism(s)
mplicated in renal fibrosis in patients with
CKD2/FJHN remains highly speculative. A
irect relationship between uromodulin and col-
agen metabolism cannot be ruled out because no
tudy addressing this aspect has been published
o date, and this represents an interesting area for
uture research. What we can reasonably exclude
s a relationship with the antibacterial functions
f uromodulin28 because the frequency of epi-
odes of urinary tract infection is not increased in
atients with MCKD2/FJHN, and, probably, wild-
ype uromodulin secretion overcomes the antibac-
erial requests in these patients. Moreover, lack
f renal fibrosis in Umod/ mice at 24 months
f age is strongly against this possibility.31 Con-
ersely, several observations suggested that uro-
odulin may have direct inflammatory proper-
ies because it modulates cytokine secretion by
onresident monocytes79 and granulocytes80;
herefore, upregulation by mutated isoforms
hould be excluded.
Finally, tubulointerstitial nephritis in the TAL
an be induced in rabbits and rats after adminis-
ration of uromodulin.81,82 Clinical studies
howed uromodulin deposits in tubular inter-
titium in several human conditions character-
zed by tubulointerstitial fibrosis, including
CKD.66,67,81 Uromodulin is a powerful im-
unogen, and antiuromodulin antibodies have
een localized in renal interstitium after uromodu-
in administration to rats.82,83 Healthy humans
o not produce antiuromodulin antibodies for
egregation of the protein at the luminal face of
ubular cells. However, loss of cell polarity or
ltered cell processing, such as accumulation in
he ER, could interfere with proteosome degrada-
ion84 of misfolded mutant protein, determining
asal localization. The only 2 studies showing
mmunopathologic data for kidneys of patients
ith proven UMOD mutations do not show uro-
odulin interstitial deposits,9,10 ruling out this
echanism. Alternatively, renal fibrosis could be
he consequence of inflammatory and immune
esponses mediated by upregulation of nuclear
actor-B, which is a key step in the ER overload
esponse pathway.85 iystogenesis
Despite the name of the disease incorporating
he term “cystic,” medullary cysts are not a
ommon finding in patients with MCKD2.86
edullary cysts derive from enlargements of
ollecting tubules and remain connected to the
ephron of origin. In patients with GCKD, cyst
ilatations occur prevalently at the Bowman’s
pace level and may be extended to some tu-
ules. This appears to be different from patients
ith PKD, for whom cysts arise in every tubule
egment and rapidly close off from the nephron
f origin.87 Therefore, cystogenesis in patients
ith MCKD2 and GCKD should follow differ-
nt mechanisms. The small cysts described in
atients with MCKD2 could arise from tubule
ilatation, possibly caused by water income,
hich would be expected in the absence of a
romodulin water barrier in the TAL. However,
he reason for the scattered involvement and
ide interfamilial and intrafamilial variability
emains unknown. Based on our current lack of
nowledge on the topics, hypothetical effects of
odifier genes or a 2-hit mechanism having a
ole in selected segments of the same kidney
annot be excluded. Conversely, glomerular cysts
re a constant feature in affected members of a
amily with GCKD with UMOD mutations.10
tudies that appeared in the mid-1970s showed
n abnormal presence of uromodulin within glo-
erular cysts66 in patients who obviously were
ot characterized on molecular grounds. In our
ands, immunohistologic examination did not
how uromodulin in enlarged Bowman’s space.
espite these inconsistencies, we hypothesized a
echanism of dilatation of Bowman’s space
inked to tubular obstruction that would deter-
ine urine reflux and in some way mimic an
bstructive condition. As discussed, the experi-
ental generation of glomerular cysts by ureteric
igation in fetal sheep65 reinforces our hypoth-
sis.
yperuricemia
Hyperuricemia is a common feature in pa-
ients with MCKD2/FJHN, involving approxi-
ately 65% to 75% of patients without relevant
nterfamilial and intrafamilial differences. It is
aused by an increment in tubular reabsorption
f urates; this defect is unique among any other
nherited conditions.1,39,87
e
a
a
m
p
r
t
i
g
e
r
t
p
2
p
b
p
a
w
a
u
t
(
v
l
t
h
t
r
2
r
t
w
a
t
d
f
m
h
n
C
t
a
t
l
v
c
e
p
t
s
s
m
c
t
i
e
t
a
F
u
c
n
c
d
6
e
t
n
p
G
I
l
a
2
n
t
3
U
d
J
t
e
6
m
t
o
h
u
SCOLARI ET AL996A point of interest is to look at clinical param-
ters that correlate with hyperuricemia. We found
n inverse correlation between urine osmolality
nd uric acid levels in 26 carriers of UMOD
utations (Fig 2), suggesting an implication of
lasma volume in hyperuricemia. Bleyer et al13
eported fractional excretion of uric acid greater
han 5% in 18 of 41 affected patients, with an
nverse correlation with creatinine clearance, sug-
esting an effect of renal function on this param-
ter. The net balance of urate excretion is the
esult of reabsorption, secretion, and postsecre-
ory reabsorption. In human kidneys, the first 2
hases are confined to the proximal tubule, where
specific transporters,88 ie, human urate trans-
orter and human urate transporter/channel, have
een characterized.89,90
Much less is known about the secretion and
ostsecretion of urate in nephron segments. Avail-
ble data for uromodulin localization in patients
ith normal and pathological conditions18 argue
gainst a direct implication of uromodulin in
rate reabsorption. Based on the strong correla-
ion between hyperuricemia and urine osmolality
which gives an indirect estimate of water depri-
ation), we hypothesize an indirect mechanism
inked to volume contraction and maintenance of
he countercurrent gradient by uromodulin that
as already been discussed for water reabsorp-
ion. The association between reduced sodium
eabsorption in the TAL, ie, activity of the Na-K-
Cl cotransporter, and hyperuricemia has been
eported as a side effect of long-term administra-
ion of loop diuretics91 and in 50% of patients
ith Bartter’s syndrome, a variant of which is
ssociated with mutations of the gene encoding
he Na-K-2Cl cotransporter.92 The decreased so-
ium uptake in the TAL would be compensated
or by enhanced sodium reabsorption in the proxi-
al tubule that would increase the activity of the
uman urate transporter.91 Additional studies are
eeded to show this hypothesis.
ONCLUSIONS: UMOD-RELATED CONDITIONS
AS A MODEL OF RENAL STORAGE DISEASE
It appears from the review of the recent litera-
ure on UMOD mutations that they are associ-
ted with a variable panel of symptoms that, in
he past, have been associated with specific patho-
ogical states. Most frequently, mutations in-
olve cysteine residues in 1 of the predicted MbEGF domains, with a cluster of mutations at
xons 4 and 5. This occurs independently in
atients with MCKD2 and FJHN, suggesting
hat the artful distinction between the 2 entities
hould not exist. Cell biology experiments
howed that misfolded uromodulin has delayed
aturation and accumulates in the ER. Lack of
ellular uromodulin function impairs tubular func-
ion, particularly water reabsorption, determin-
ng water depletion and hyperuricemia. The pres-
nce of mutant uromodulin aggregates could
rigger a stress response in the cell that might be
key step in the pathogenesis of these disorders.
or this reason, we propose the definition of
romodulin storage disease for the mentioned
onditions with proven UMOD mutations.
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